ArticleFolia microbiologica2026
Anti-Candida albicans and anti-virulence activities of vaginal Lactobacillus strains from asymptomatic women: phenotypic characterization and prediction of antimicrobial peptide gene clusters.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Harnessing probiotics against candidiasis: a systematic review of experimental and mechanistic evidence.Frontiers in cellular and infection microbiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal candidiasis (VVC) is a prevalent mucosal infection primarily caused by Candida albicans, affecting up to 75% of women of reproductive age. VVC therapeutic management is increasingly challenged by antifungal resistance, host toxicity, and high recurrence rates. Lactobacillus species, the dominant members of healthy vaginal microbiota, are known to antagonize pathogens and maintain mucosal homeostasis by producing antimicrobial metabolites and modulating epithelial responses. However, few studies have explored the antagonistic and anti-virulence properties of Lactobacillus strains isolated from asymptomatic women, particularly their activity against clinical C. albicans isolates. This study aimed to characterize vaginal Lactobacillus strains and their cell-free supernatants (CFS) isolated from asymptomatic women and evaluate their antifungal and anti-virulence activities against clinical isolates of C. albicans. Forty-two clinical Lactobacillus isolates were identified, of which eight inhibited the growth of the tested pathogens. However, among the clinical isolates, only L. fermentum JAC 231 and Lactiplantibacillus plantarum MDBL 269 inhibited all the fungal isolates tested. Based on these results, L. fermentum ATCC 23271 (positive control) and the clinical strains L. fermentum JAC 231 and L. plantarum MDBL 269 were selected for detailed analyses of their ability to interfere with key virulence factors of C. albicans, including hyphal morphogenesis, biofilm formation and disruption, adhesion, and the secretion of extracellular enzymes. The selected strains and their CFS displayed antagonistic activity: they reduced pathogen adhesion, co-aggregated with yeast cells, impaired biofilm formation, and destabilized preformed biofilms. In addition, whole-genome sequencing combined with antimicrobial peptide gene-cluster prediction using BAGEL4 and antiSMASH revealed two biosynthetic gene clusters in L. fermentum JAC 231 and seven in L. plantarum MDBL 269, providing a plausible genetic basis for the antimicrobial effects observed.
Indexed as
Identifiers
42371250What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.